Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received a consensus recommendation of “Hold” from the seven ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $4.93.

A number of research analysts have issued reports on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a report on Thursday, March 14th. HC Wainwright restated a “buy” rating and set a $5.00 price target (up previously from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. Finally, StockNews.com started coverage on shares of Sangamo Therapeutics in a research report on Tuesday, February 13th. They set a “sell” rating on the stock.

Sangamo Therapeutics Trading Up 7.3 %

NASDAQ SGMO opened at $0.67 on Friday. The company has a fifty day simple moving average of $0.79 and a two-hundred day simple moving average of $0.62. The stock has a market cap of $119.91 million, a P/E ratio of -0.46 and a beta of 1.44. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.82.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its position in Sangamo Therapeutics by 0.3% during the second quarter. BlackRock Inc. now owns 15,888,976 shares of the biopharmaceutical company’s stock worth $20,656,000 after acquiring an additional 48,282 shares during the last quarter. Wasatch Advisors LP boosted its position in Sangamo Therapeutics by 7.8% during the first quarter. Wasatch Advisors LP now owns 13,642,417 shares of the biopharmaceutical company’s stock worth $24,011,000 after acquiring an additional 991,663 shares during the last quarter. Vanguard Group Inc. boosted its position in Sangamo Therapeutics by 10.5% during the third quarter. Vanguard Group Inc. now owns 12,731,109 shares of the biopharmaceutical company’s stock worth $62,383,000 after acquiring an additional 1,205,951 shares during the last quarter. State Street Corp boosted its position in Sangamo Therapeutics by 25.3% during the first quarter. State Street Corp now owns 7,775,327 shares of the biopharmaceutical company’s stock worth $45,175,000 after acquiring an additional 1,570,740 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Sangamo Therapeutics by 12.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,444,283 shares of the biopharmaceutical company’s stock worth $10,815,000 after acquiring an additional 373,442 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.